The Effects of Probiotic On Serum Lipid Profiles in Patients with type 2 Diabetes Mellitus: A Randomized Clinical Trial

Tahere Tofighiyan¹, Akram Kooshki^2, , BiBi Leila Hoseini³ and Maryam Mohammadi⁴

¹Department of Nursing, School of Nursing and Midwifery, Sabzevar University of Medical Sciences, Sabzevar, Iran

²Department of Nutrition & Biochemistry, School of Medicine, Sabzevar University of Medical Sciences, Sabzevar, Iran

³School of Nursing and Midwifery, Sabzevar University of Medical Sciences, Sabzevar, Iran

⁴Department of Public Health, School of Health, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Cite this paper:
Tahere Tofighiyan, Akram Kooshki, BiBi Leila Hoseini and Maryam Mohammadi. The Effects of Probiotic On Serum Lipid Profiles in Patients with type 2 Diabetes Mellitus: A Randomized Clinical Trial. Journal of Food and Nutrition Research. 2016; 4(12):795-798. doi: 10.12691/jfnr-4-12-5

Abstract

Background & Objectives: With regard to probable mechanisms about probiotics effect in cholesterol lowering and since final conclusion about fat-lowering effect of probiotics is not clear; Present study has been conducted to determine effect of probiotics on serum lipid profile level of patients with type II diabetes mellitus. Material and Methods: This double-blind randomized, clinical trial study was done on 44 type-2 diabetic patients, by available sampling. Patients were allocated to either case or control groups by permuted block randomization. Probiotic group received one probiotic tablet and placebo group received one placebo tablet daily for 8 weeks. At baseline and the end of study, 5 ml blood was collected from each patient after a 14-h fasting in order to measure serum lipid profile. Data were analyzed by descriptive and analytic statistics. Results: Demographic parameters, anthropometric and dietary factors were not significantly different between two groups at baseline and the end of week 8. Probiotic intake caused significant decrease in serum total cholesterol (p=0.0001), LDL (p=0.001) and increase serum HDL (p=0.001) in probiotic group. Results showed that observed difference in LDL and HDL between 2 groups was not significant, but serum cholesterol had a significant difference between 2 groups. Conclusions: This study showed that probiotic supplementation is probably effective in improving risk factors for cardiovascular diseases in type 2 diabetes, via serum lipid profile reduction.

Keywords:
probiotics serum lipids diabetes mellitus type 2

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]	Marion, J.F. Medical nutrition therapy for diabetes mellitus and hyperglycemia of non-diabetic origin. Food, nutrition and diet therapy. Eds.: Philadelphia: W.B. Saunders Company, 10nd ed., 742-780, 2004.
[2]	Wild, S., Roglic, G., Green, A., Sicree, R., King, H. Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030. Diabetes Care, 27, 1047-1053, 2004.
[3]	Greenland, P., Knoll, M.D., Stamler, J., Neaton, J.D., Dyer, A.R., Garside, D.B. Major risk factors as antecedents of fatal and nonfatal coronary heart disease events. Journal of the American Medical Association, 290, 891-897, 2003.
[4]	Jairath. N. Coronary Heart Disease & Risk Factor management. Philadelphia: W.B. Saunders Company, 1999.
[5]	Arauz-Pacheco, C., Parrott, M.A., Raskin, P. American Diabetes Association. Treatment of hypertension in adults with diabetes. Diabetes Care, 26, 80-82, 2003.
[6]	Franz, M.J., Bantle, J.P., Beebe, C.A., Brunzell, J.D, Chiasson, J.L., Garg, A. Evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes and related complications. Diabetes Care, 25, 148-198, 2002.
[7]	WHO, Diet, nutrition and prevention of chronic diseases, Report of a joint WHO/FAO expert consultation. Geneva: Switzerland, 2003.
[8]	Bliznakov, E.G. Lipid-lowering drugs (statins), cholesterol and coenzyme Q10. Biomedicine and Pharmacotherapy, 56, 56-59, 2002.
[9]	Kumar, M., Nagpal, R., Kumar, R., Hemalatha, R., Verma, V., Kumar, A. Cholesterol-lowering probiotics as potential bio-therapeutics for metabolic diseases. Hindawi Publishing Corporation, experimental diabetes research, 2012.
[10]	Ooi, L.G., Liong, M.T. Cholesterol-lowering effects of probiotics and prebiotics: A review of in vivo and in vitro findings. International Journal of Molecular Sciences, 17, 2499-2522, 2010.
[11]	Ratna Sudha, M., Chauhan, P., Dixit, K., Babu, S., Jami K. Probiotics as complementary therapy for hypercholesterolemia. Biology and Medicine, 1, 4, 2009.
[12]	Greany, K.A., Bonorden, M.J., Hamilton-Reeves, J.M., McMullen, M.H., Wangen, K.E., Phipps, W.R. Probiotic capsules do not lower plasma lipids in young women and men. European Journal of Clinical Nutrition, 62, 232-237, 2008.
[13]	Hatakka, K., Mutanen, M., Holma, R., Saxelin, M., Korpela, R. Lactobacillus rhamnosus LC705 together with propionibacterium freudenreichii SSP shermanii JS administered in capsules is ineffective in lowering serum lipids. The Journal of the American College of Nutrition, 27, 441-447, 2008.
[14]	Liong, M.T., Shah, N.P. Bile salt deconjugation ability, bile salt hydrolase activity and cholesterol co-precipitation ability of lactobacilli strains. International Dairy Journal, 15, 391-398, 2005.
[15]	Ataie-Jafari, A., Larijani, B., Alavi, M., Tahbaz, F. Cholesterol-lowering effect of probiotic yogurt in comparison with ordinary yogurt in mildly to moderately hypercholesterolemia subjects. Annals of Nutrition and Metabolism, 54, 22-27, 2009.
[16]	Lewis, S.J., Burmeister S. A double-blind placebo-controlled study of the effects of Lactobacillus acidophilus on plasma lipids. European Journal of Clinical Nutrition, 59, 776-780, 2005.
[17]	Ejtahed, H., MohtadiNia, J., HomayouniRad, A., Niafar, M., AsghariJafarabadi, M., Mofid, V. The effects of probiotic and conventional yoghurt on diabetes markers and insulin resistance in type 2 diabetic patients: A randomized controlled clinical trial. Iranian Journal of Endocrinology and Metabolism, 13, 1-8, 2011.
[18]	Smet, I.1., Boever, P., Verstraete, W. Cholesterol lowering in pigs through enhanced bacterial bile salt hydrolase activity. British Journal of Nutrition, 79,185-194, 1998.
[19]	Klaver, F.A., vanderMeer, R. The assumed assimilation of cholesterol by lactobacilli and Bifidobacterium bifidum is due to their bile salt-de conjugating activity. Appl Environ Microbiol, 59, 1120-1124, 1998.
[20]	Usman, A. Hosono: Bile tolerance, taurocholate de conjugation, and binding of cholesterol by Lactobacillus gasseri strains. Journal of Dairy Science, 82, 243-248, 1999.
[21]	Pereira, D.I., Gibson, G.R. Effects of consumption of probiotics and prebiotics on serum lipid levels in humans. Critical Reviews in Biochemistry and Molecular Biology, 37, 259-281, 2002.
[22]	Ejtahed, H., MohtadiNia, J., HomayouniRad, A., Niafar, M., Asghari, M., Mofid, V. The effects of probiotic yoghurt consumption on blood pressure and serum lipids in type 2 diabetic patients: Randomized clinical trial. Iranian Journal of Nutrition Sciences & Food Technology, 6, 1-12, 2012.
[23]	Tomaro-Duchesneau, C., Jones, M.L., Shah, D., Jain, P., Saha, S, Prakash S: Cholesterol Assimilation by Lactobacillus Probiotic Bacteria: An in vitro investigation. BioMed Research International 2014. Article ID 380316.
[24]	Lin, S.Y., Ayres, J.W., Winkler, J.r., Sandine, W.E. Lactobacillus effects on cholesterol: in vitro and in vivo results. Journal of Dairy Science, 72, 2885-2899, 1998.
[25]	Vanderpool, C., Yan, F., Polk, B. Mechanisms of probiotic action: Implications for therapeutic applications in inflammatory bowel diseases. Inflammatory Bowel Diseases, 14, 1585-1596, 2008.
[26]	Mosaffa, N. Probiotics as a new generation of living drugs. Journal of Research in Medical Sciences, 32, 169-174, 2008.